Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76484 | 0.89 | CYP19A1 (0.53) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL29416717 | 0.89 | CYP19A1 (0.53) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL13697102 | 0.88 | CYP19A1 (0.39) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL4826058 | 0.87 | CYP19A1 (0.52) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL13930401 | 0.87 | CYP19A1 (0.60) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL13930391 | 0.87 | CYP19A1 (0.60) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL2322371 | 0.84 | ESR1 (0.58) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL4828637 | 0.83 | ESR1 (0.49) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL4828631 | 0.83 | ESR1 (0.49) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL13511000 | 0.81 | PTGS2 (0.55) | CYP19A1CYP11B2PTGS2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090236975-A1 | SILICON-CONTAINING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE UTILIZING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090236975-A1 | SILICON-CONTAINING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE UTILIZING THE SAME | ESPL1, EML4, EED | CYP19A1 1484/4885CYP11B2 4103/4885PTGS2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.